Wednesday, January 23, 2019
AbbVie initiated at UBS
AbbVie assumed with a Neutral at UBS. UBS analyst Navin Jacob assumed coverage of AbbVie with an unchanged Neutral rating and lowered his firm’s price target for the shares to $91 from $97. While the Humira biosimilar threat has been de-risked, the current valuation offers limited upside, says the analyst.
https://thefly.com/landingPageNews.php?id=2852061
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.